Ajanta Pharma Announces the Launch of Risperidone Tablets

BRIDGEWATER, N.J., May 9, 2014 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announced today the launch of Risperidone Tablets (0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg), the generic version of Risperdal®[1].  Risperidone Tablets are used to treat schizophrenia and bipolar disorder.  According to IMS Health, sales of branded and generic products totalled approximately $147 million for the 12 months ending March 2014[2].

Ajanta Pharma's launch of Risperidone Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market.  To date, two ANDAs have been approved with another 21 ANDAs pending US Food and Drug Administration approval.

About Ajanta Pharma
Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India.  Over 4,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30 countries.  Its mission is to serve global healthcare needs through empathy, innovation and technology. 

For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com

[1] Risperdal is a registered trademark of Janssen Pharmaceuticals
[2] IMS Health, National Sales Perspectives, March 2014

SOURCE Ajanta Pharma USA Inc.